Polyrizon Provides 2025 and Recent Highlights

Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements

Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, provided 2025 and recent a business update.

"Polyrizon has delivered significant progress across its innovative nasal programs, including key regulatory advancements with the FDA, preparation for potential human clinical trials, and valuable medical collaborations, all powered by a strong cash position and a debt-free balance sheet,” said Tomer Izraeli, chief executive officer of Polyrizon.

Key Highlights of Polyrizon’s Achievements in 2025 and Recent Highlights:

• As of December 31, 2025, the Company’s cash and cash equivalents totaled approximately $17.5 million.
• Completed a productive FDA Pre-Submission Meeting for the PL-14 (NASARIX™) Allergy Blocker, discussing clinical development strategy and potential human trials.
• Submitted a Pre-Request for Designation (Pre-RFD) to the FDA for the PL-16 Viral Blocker.
• Announced GMP manufacturing of Clinical Trial Material with Eurofins CDMO in preparation for U.S. clinical studies.
• Signed an agreement with a leading global Preclinical CRO to support the clinical development pathway, with studies expected to commence in Q2 2026.
• Reported positive preclinical results for the intranasal Naloxone Hydrogel program, demonstrating enhanced nasal deposition and mucoadhesion.
• Achieved successful intranasal delivery results for PL-14 and completed a key manufacturing upscaling milestone for the nasal spray platform.
  
  

In addition, the Company completed the branding process for its allergy blocker under the name NASARIX™, reported encouraging preclinical data across multiple programs and announced non-binding initiatives to explore potential revenue-generating investment opportunities in high-growth sectors, including potential stakes in private aviation and advanced eVTOL drone technologies, while maintaining full financial flexibility thanks to its strong cash reserves and debt-free status.

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T.